Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMP301 in recurrent low-grade serous ovarian cancer
NL-OMON58737Phase 3Recruiting
- Sponsor
- Verastem Oncology
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avutometinib and defactinib in low-grade serous ovarian carcinoma (LGSOC) (2 arms), sponsored by Verastem Oncology. Primary endpoint: Progression-free survival. Started Apr 2025; status: recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)
Beyond the preview
Go deeper on NL-OMON58737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58737.